Creso Pharma is distinguishing itself by focusing on pharmaceutical-grade cannabis products to generate higher margins for investors.

Creso Pharma established itself as an early mover in the medicinal cannabis industry, making significant inroads in 2017. The company has a diverse product portfolio of cannabis and hemp derived products that focus on four key areas: therapeutics, nutraceuticals, animal health and cosmetics.

Since 2017, it has been committed to build a business rather than ride a trend, albeit a lucrative one.

The legal cannabis market is forecast to reach US$148 billion by 2026, with Barclays European Consumer Staples Report predicting the global cannabis market will reach US$272 billion by 2028.

Within this environment, Creso is aggressively pursuing further commercialisation of nine pharmaceutical-grade products, along with key certifications and strategic partnerships that will accelerate revenue growth.

Creso has already commercialised four sales generating products across the cosmetics, animal health, nutraceuticals and therapeutics verticals and expects its growth plans to be supported by secure funding, increasing revenue, prudent cost management and experienced leadership as it strives to unlock the full value of its operations on behalf of its shareholders.

This comes on the back of a tumultuous six months which Canadian cannabis giant PharmaCielo Limited (TSX-V:PCLO), which targeted Creso for the breadth and strength of its current portfolio and widespread cannabis operations and valued it at A$122 million.

The deal fell over in November, however it highlighted the potential investment opportunity in the Australian company. The proposed takeover, valued Creso at 63 cents per share representing a 50% premium to the company’s closing price on 6 June, 2019.

Creso’s strengths are emphasized by its year-on-year revenue growth, providing a sound base as new products are brought to market.

Creso Pharma believes the value of its fundamental operations continues to grow, supported by the company’s portfolio of products, established operations, corporate interest and global market opportunities.

Creso Pharma’s global market penetration as at December 2019. To find out more about Creso Pharma visit Next Biotech Stocks

Product strength

Creso Pharma’s products are made with standardised dosing and formulations through the application of pharmaceutical rigour, Good Manufacturing Practices (GMP) standards and proprietary, innovative delivery technologies.

In addition, they carry the well-known "Swiss Made" label that is synonymous with premium-quality products.

In human health, Creso Pharma anticipates signing with more commercial partners to expand the commercial reach of its two existing products cannaQIX® 10 and cannaQIX® 50 and to introduce the newly developed products in additional European countries.

The company is prioritising Spain, Portugal, the Scandinavian countries, Poland and Israel.

Creso advised that launch preparations of the cannaQIX® range with leading South African pharmaceutical company, Pharma Dynamics, a subsidiary of Lupin Limited (NSE:LUPIN) in the March quarter of 2020 are on schedule.

In animal health, Creso Pharma's partner Virbac is introducing the two initial anibidiol® products into further countries in Europe and will be launching Creso Pharma's new animal health products in the near future.

For both human and animal health, Creso Pharma has initiated its reach into North America, where it is in discussions with a number of potential partners to introduce all 13 products, human and animal, into selected US states.

In South America, Creso Pharma has filed its animal health products in Argentina and Uruguay together with PharmaCielo and is at the last stage of approval.

Commercial partners have been identified, terms negotiated, and a plan outlined for a long term collaboration on the existing range of products as well as on the new products that Creso Pharma has developed which are ready for launch.

To find out more about Creso Pharma visit Next Biotech Stocks

Jonathan Jackson

Creso set for pharmaceutical cannabis expansion in 2020